Compare BridgeBio Pharma Inc (BBIO) vs Braze Inc (BRZE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Braze Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Braze Inc trades at $28.27 (market cap $3.24B). The key difference: BridgeBio Pharma Inc is far larger — about 5.1× Braze Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | BRZE | |
|---|---|---|
Market Cap | $16.61B | $3.24B |
Sector | Health | Technology |
52-Week High | $90.17 | $36.19 |
52-Week Low | $47.29 | $15.79 |
Enterprise Value | $18.16B | $2.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Braze (BRZE) trades at $26.54, up 3.23% with bullish technical signals from moving averages. The company shows strong revenue growth trajectory from $238M in 2022 to $593M in 2025, though profitability remains elusive with a -15.51% net margin. Recent Q1 2027 earnings met expectations at $0.10 per share, while analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $34.78 consensus target representing 31% upside potential.
The investment case hinges on Braze's accelerating revenue growth and market leadership in customer engagement software, offset by persistent losses and insider selling. While technical indicators support near-term momentum, execution on profitability remains the key catalyst for sustained upside. Risks include competitive pressures and the company's ability to convert growth into sustainable earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
